A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
about
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureTherapeutic Strategies to Treat Dry Eye in an Aging PopulationDry eye: an inflammatory ocular diseaseThe pathophysiology, diagnosis, and treatment of dry eye diseaseManaging Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.Post-LASIK dry eyeAging: a predisposition to dry eyes.Cataract surgery in patients with ocular surface disease: An update in clinical diagnosis and treatment.Dry eye disease: A review of diagnostic approaches and treatmentsSafety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryOcular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.A clinical study of the efficacy of topical corticosteroids on dry eye.Effects of corneal nerve density on the response to treatment in dry eye disease.Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture.Low humidity environmental challenge causes barrier disruption and cornification of the mouse corneal epithelium via a c-jun N-terminal kinase 2 (JNK2) pathwayTherapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental systemExpert opinion in the management of aqueous Deficient Dry Eye Disease (DED).Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseTopical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in ChinaTreating Sjögren's Syndrome: Insights for the ClinicianTopical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.Observation of Influence of Cataract Surgery on the Ocular Surface.Tear cytokine profiles in dysfunctional tear syndrome.Biodegradable PLGA-Based Drug Delivery Systems for Modulating Ocular Surface Disease under Experimental Murine Dry EyeDry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome.Dry eye disease: an immune-mediated ocular surface disorder.Treatment of chronic dry eye: focus on cyclosporineComparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery.Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations.New agents for treating dry eye syndrome.Allergic conjunctivitis: a comprehensive review of the literature.Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.Changing trends in the treatment of dry-eye disease.An update on dry eye disease molecular treatment: advances in drug pipelines.Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?The role and treatment of inflammation in dry eye disease.Safety of treatments for primary Sjögren's syndrome.The Matrix Metalloproteinase 9 Point-of-Care Test in Dry EyeOcular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice.
P2860
Q26764956-FE7ABB6B-457A-4145-BF8E-67EEB46CF110Q26822610-6DA69D31-7E85-4879-9825-3FA024C3C237Q26852044-538E154C-40F4-4736-9CF2-63AC9821A372Q28083825-84CB1267-BA5D-453B-BAE8-10DF0AB7AD35Q34028408-D535B684-EC56-425D-80DA-9D4C22E181B1Q34102815-FB774181-458E-4BC1-B2FF-22C1F7F46B43Q34114336-D331D3E7-F9F9-4C36-8CA1-A513936F9BE6Q34273377-12304746-6D51-4E3C-97FA-2F3904249C25Q34273384-058BB585-CE02-4604-8589-F374BC68B8EDQ34606700-7A4A218D-8B0A-4F43-82D5-B52E80DD2E69Q34627019-50306F12-2D88-44FF-9596-2EBE27568602Q34943771-A6875541-1EFB-4DA9-9DC2-1601D52F2BE6Q35214116-B02C1449-7D6B-43D6-87CE-7FD0EF581DCAQ35570793-BE69429E-3514-4BBA-B133-071937B69D12Q35675281-0821A891-C4B8-449B-8B0B-BCF8AC1782E2Q35768484-FC167A03-B516-4397-B0EF-7BEAB636F285Q35805082-5740CFB5-7D73-4E82-BAB1-EA039600321EQ35907009-7E27ED08-40CE-4CC5-95A0-0C1D40C98CA8Q36009560-B3DE150D-EF6F-4F3D-8EA7-99F3333AC9E8Q36056942-47610C7F-E95C-46E6-9B6F-5D5EB0A6EF77Q36099684-B583F10C-4AF4-4C3C-9D32-BB0E6725B431Q36151353-871AEAB0-3191-4DCE-88B0-74FAD4A7E00BQ36637791-39A75369-F6FC-4305-8F00-8BBE730C612BQ36734622-83F4982F-E17E-4B5E-8783-0DC49E64A959Q36829070-02F0B316-F32F-4006-9223-7484C75937F6Q36908429-42F8ECE5-3E35-4EBA-9D60-652A9C32A58EQ36916372-6AC02C2E-2E4F-4040-9134-3CA4734BCAD2Q37236096-397228FC-8C64-4F1F-887B-1CE425925A02Q37608776-EB4E3A3D-4384-487A-9CB9-545B702D3FCDQ37642288-993E2D3A-35FF-4119-AD7E-E8385B5D55E5Q38058002-C8DBD8A4-482D-4251-A9CC-9BF95ACA3979Q38089973-DCD07936-2CE2-49CA-B2BE-CC56B0E214FAQ38112375-D78FD7EB-5D9C-4C1D-BAB7-703487F9A178Q38148616-119C0910-8BB5-4396-BCE9-CA5C60DCD3ABQ38207723-1833C862-EEBC-4348-9C21-168B502B0454Q38241140-D5F45980-6A94-455D-9A3C-3ABF8254C99EQ38270449-D71A75E3-11F3-4B6A-B341-89214EF2181EQ38711144-81756460-F7DC-4C78-B0CF-1E6F47C74418Q38724515-C23C2748-1BFA-4473-B8B7-F49FF30AD3A7Q38774962-AADCCE93-B2C1-46AF-ACB0-1B01C9DFB2C2
P2860
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A randomized, double-masked, p ...... s with delayed tear clearance.
@en
A randomized, double-masked, p ...... s with delayed tear clearance.
@nl
type
label
A randomized, double-masked, p ...... s with delayed tear clearance.
@en
A randomized, double-masked, p ...... s with delayed tear clearance.
@nl
prefLabel
A randomized, double-masked, p ...... s with delayed tear clearance.
@en
A randomized, double-masked, p ...... s with delayed tear clearance.
@nl
P2093
P1476
A randomized, double-masked, p ...... s with delayed tear clearance.
@en
P2093
Bruce Anderson
Edward J Holland
Howard M Proskin
James Chodosh
Roger Vogel
Stephen C Pflugfelder
Stephen P Bartels
Steven L Maskin
Teresa Micuda
P304
P356
10.1016/J.AJO.2004.04.052
P407
P577
2004-09-01T00:00:00Z